• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

Novo Nordisk CEO to step down as obesity drug competition intensifies

by May 17, 2025
by May 17, 2025

Novo Nordisk said on Friday that Chief Executive Officer Lars Fruergaard Jørgensen will step down, a decision made jointly with the board as the company confronts mounting competitive and financial pressures.

The changes are being made “in light of the recent market challenges Novo Nordisk has been facing, and the development of the company’s share price since mid-2024,” the company said.

The Danish drugmaker said Jørgensen would remain in place “for a period” to help ensure a smooth leadership transition.

A formal search for his successor is underway, with an announcement expected in due course.

Jørgensen’s departure comes at a time when the company’s performance has been under scrutiny.

Shares in the pharmaceutical firm fell by more than 4% following the announcement in Copenhagen, while its US-listed stock dropped 5.61% in premarket trading.

The company’s shares have lost more than 24% of their value so far this year in the US, and close to 35% in Copenhagen.

Meanwhile, Eli Lilly has lost only about 5.8% YTD. Its share price was up by 1.36% in pre-market trading.

In a statement, Novo Nordisk said the decision was the result of internal discussions initiated by the Novo Nordisk Foundation, which considered the merits of accelerating CEO succession.

“Novo Nordisk’s strategy remains unchanged, and the Board is confident in the company’s current business plans and its ability to execute on the plans,” said Chairman Helge Lund.

Jørgensen’s tenure saw early success of Wegovy, Ozempic before Eli Lilly took over

Jørgensen has been with Novo Nordisk since 1991 and took over as CEO in 2017.

Under his leadership, the company cemented its lead in the growing global market for obesity and diabetes treatments, largely thanks to the success of Wegovy and Ozempic.

These drugs contributed to soaring sales and investor enthusiasm, turning Novo Nordisk into one of Europe’s most valuable companies.

However, recent developments have rattled investor confidence.

Eli Lilly’s obesity drug Zepbound has steadily gained traction in the United States, surpassing Wegovy in prescriptions since mid-March.

Meanwhile, results from Novo’s trials for next-generation obesity treatments have fallen short of expectations, casting doubts over the company’s future product pipeline.

Strategic partnerships to defend market share

In response to the competitive threat, Novo Nordisk has pursued several strategic partnerships.

Just a day before the CEO announcement, the company signed a collaboration agreement with biotech firm Septerna, potentially worth up to $2.2 billion.

The partnership aims to discover up to four new obesity therapies, with Septerna eligible for over $200 million in upfront and near-term payments.

Novo has also sought to expand access to its existing treatments through US telehealth firms like Hims & Hers, Ro, and LifeMD.

These partnerships allow for direct-to-patient distribution of Wegovy in the US, amid tighter regulations on compounding pharmacies that previously filled the gap during drug shortages.

Despite these efforts, the CEO transition marks a critical moment for Novo Nordisk as it navigates a more crowded and aggressive market landscape.

The post Novo Nordisk CEO to step down as obesity drug competition intensifies appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Why this investment bank sees more than 30% upside on Meta
next post
Rich List 2025: UK billionaires decline for first time in years amid market turmoil

Related Posts

Nvidia shares continue golden run, hit fresh highs:...

June 28, 2025

Nike stock rallies 15%: 3 reasons why shoemaker’s...

June 28, 2025

Russell 2000 to reach a new all-time high...

June 28, 2025

Germany says DeepSeek illegally sends data to China,...

June 28, 2025

Microsoft’s new AI chip delayed to 2026: report

June 28, 2025

London braces for scorching heatwave, hottest start to...

June 28, 2025

Snap stock: 3 reasons why it looks better...

June 28, 2025

Citi Wealth CIO says traders ignoring warning signs...

June 28, 2025

JPM, BAC – two gold standard bank stocks...

June 28, 2025

Roger Federer joins elite ranks of athlete billionaires

June 28, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • Nvidia shares continue golden run, hit fresh highs: analysts remain firmly bullish

    June 28, 2025
  • Nike stock rallies 15%: 3 reasons why shoemaker’s shares are rising today

    June 28, 2025
  • Russell 2000 to reach a new all-time high within 5 months: here’s why

    June 28, 2025
  • Germany says DeepSeek illegally sends data to China, urges Apple, Google to review app

    June 28, 2025
  • Microsoft’s new AI chip delayed to 2026: report

    June 28, 2025
  • London braces for scorching heatwave, hottest start to Wimbledon expected

    June 28, 2025

Editors’ Picks

  • 1

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 2

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 5

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025
  • 6

    Elon Musk says federal employees must fill out productivity reports or resign

    February 23, 2025
  • 7

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025

Categories

  • Economy (1,653)
  • Editor's Pick (171)
  • Investing (185)
  • Stock (1,072)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

Here’s why AMC stock price may jump...

March 20, 2025

Can Espinosa’s turnaround plan revive Nissan’s falling...

May 15, 2025

Why two Wall Street firms remain cautious...

June 2, 2025